3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Neoplasm Metastasis
1
Breast Neoplasms
1
Breast Cancer Metastatic
1
Interventions
Fulvestrant
6
Letrozole
4
Capecitabine
4
exemestane
3
dalpiciclib
3
Trastuzumab
3
Docetaxel
3
Anastrozole
3
ribociclib
2
palbociclib
2
fluzoparib
2
apatinib
2
Irinotecan
2
Gemcitabine
2
tusamitamab ravtansine
1
trastuzumab deruxtecan
1
sacituzumab govitecan
1
pyrotinib
1
pegfilgrastim
1
patritumab deruxtecan
1
olaparib
1
nirogacestat
1
margetuximab
1
irinotecan sucrosofate
1
abemaciclib
1
Zoledronic Acid
1
Vinorelbine
1
Tamoxifen
1
Rogaratinib
1
Patient Reported Outcome Measures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Cancer Metastatic
×
Liposomes
×
Breast
×
Clear all
NCT03328884
2025-04-23
Phenomenal
MedSIR
Phase 2
Completed
55 enrolled